期刊文献+

COX-2、EGFR和PgP在胃癌组织中的表达及其临床意义 被引量:5

Expressions and significance of COX-2,EGFR and PgP in gastric cancer
原文传递
导出
摘要 目的探讨胃癌组织中环氧化酶2(COX-2)、表皮生长因子受体(EGFR)和P糖蛋白(PgP)的表达及其临床意义。方法应用免疫组织化学法检测360例胃癌组织中COX-2、EGFR和PgP的表达,并结合其临床病理特点进行分析。结果 COX-2、EGFR和PgP在胃癌组织中的阳性表达率分别为83.9%、36.1%和68.6%。其中,COX-2和PgP在淋巴结转移与否的组间有统计学差异;EGFR与胃癌的侵袭程度有关联,PgP与患者的性别有关联。三者的表达与年龄、肿瘤分化程度无关。结论检测COX-2、EGFR和PgP可用于对胃癌的浸润和转移进行评估。 Objective To investigate the expressions and clinical significance of cyclooxy- genase-2(COX-2), epidermal growth factor receptor (EGFR) and P glycoprotein (PgP) in gastric cancer. Methods Protein expressions of COX-2, EGFR and PgP in gastric cancer were detected by immunohistochemical method in 360 patients. Relationship of COX-2, EGFR and PgP expressions with clinicopathological characteristics were analyzed. Results The positive expression rates of COX 2, EGFR and PgP in gastric cancer tissues were 83.90//00, 36.1~//00 and 68.6%, respectively. The expressions of COX-2 and PgP in gastric cancer tissues were correlated to lymph node metastasis (P^0. 05), but not correlated to age and tumor differentiation. EGFR expression was associated with tumor invasion. PgP expression was associated with gender. Conclusion Detection of the expressions of COX-2, EGFR and PgP is valuable in evaluating the invasion and metastasis of gastric cancer.
出处 《江苏医药》 CAS 北大核心 2013年第1期24-26,F0002,共4页 Jiangsu Medical Journal
基金 江苏省自然科学基金(BK20082321) 江苏大学高级人才启动基金(11JDC089)
关键词 环氧化酶2 表皮生长因子受体 P糖蛋白 胃癌 Cyclooxygenase-2 Epidermal growth factor receptor P-glycoprotein Gastric cancer
  • 相关文献

参考文献12

  • 1SmakmanN,Kranenburg 0, Vogten JM, et al. Cyclooxyge-nase-2 is a target of KRASD12, which facilitates the out-growth of murine C26 colorectal liver metastases[J]. ClinCancer Res,2005,11(1) :41-48. 被引量:1
  • 2Sebastian S,Settleman J,Reshkin SJ, et aL The complexity oftargeting EGFR signalling in cancer: from expression toturnover[J]. Biochim Biophys Acta,2006,1766(1) : 120-139. 被引量:1
  • 3Cascorbi I. P-glycoprotein : tissue distribution,substrates,andfunctional consequences of genetic variations[J]. Handb ExpPharmacol,2011,201 : 261-283. 被引量:1
  • 4Jamroziak K,Robak T. Pharmacogenomics of MDR1/ABCB1gene : the influence on risk and clinical outcome ofhaematological malignancies[J]. Hematology, 2004,9 ( 2 ) : 91-105. 被引量:1
  • 5张子房,尹江涛,唐炜.COX-2、p53和生存素在镇江地区胃癌患者的表达[J].江苏医药,2010,36(18):2139-2142. 被引量:5
  • 6凌斌勋,陈环球,徐新宇,周兆飞,陆建伟.C-erbB-2和EGFR在胃癌中的表达[J].江苏医药,2009,35(1):17-19. 被引量:10
  • 7Wu WK,Sung JJ,Lee CW,et al. Cyclooxygenase-2 in tumori-genesis of gastrointestinal cancers : an update on the molecularmechanisms[J]. Cancer Lett,2010,295(1) :7-16. 被引量:1
  • 8Kim N, Kim CH,Ahn DW,et al. Anti-gastric cancer effectsof celecoxib, a selective COX-2 inhibitor, through inhibition ofAkt signaling[J]. J Gastroenterol Hepatol, 2009,24(3): 480-487. 被引量:1
  • 9Liang Z,Zeng X,Gao J,et al. Analysis of EGFR,HER2,andTOP2A gene status and chromosomal polysomy in gastricadenocarcinoma from Chinese patients [J]. BMC Cancer,2008,8:363. 被引量:1
  • 10Shimura T,Kataoka H,Ogasawara N, et al. Suppression ofproHfrEGF carboxy-terminal fragment nuclear transloca-tion: a new molecular target therapy for gastric cancer [J].Clin Cancer Res,2008,14(12) :3956-3965. 被引量:1

二级参考文献18

  • 1Jing-YuanFang Zhong-HuaCheng Ying-XuanChen RongLu LiYang Hong-YinZhu Lun-GenLu.Expression of Dnmt1,demethylase,MeCP2 and methylation of tumor-related genes in human gastric cancer[J].World Journal of Gastroenterology,2004,10(23):3394-3398. 被引量:19
  • 2王剑蓉,赖仁胜.p53 codon72多态与肿瘤的相关性[J].江苏医药,2006,32(12):1138-1139. 被引量:7
  • 3Ting-Ting Wang Xiao-Ping Qian Bao-Rui Liu.Survivin:Potential role in diagnosis,prognosis and targeted therapy of gastric cancer[J].World Journal of Gastroenterology,2007,13(20):2784-2790. 被引量:42
  • 4Moghal N, Sternberg PW. Multiple positive and negative regulators of signaling by the EGF-receptor[J]. Current Opinion in Cell Biology, 1999,11(2) : 190 -196. 被引量:1
  • 5Schechter AL, Hung MC, Vaidyanathan L. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor[J].Science, 1985, 229 (4717): 976-978. 被引量:1
  • 6Menard S, Casalini P, Campiglio M, et al. HER2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer[J].Ann Oncol, 2001,12 (Suppl 1): 15-19. 被引量:1
  • 7Dursun A, Poyraz A, Celik B, et al. Expression of C-erbB-2 oncoprotein in gastric carcinoma: correlation with histopathologic characteristics and analysis of Ki-67 [J]. Pathol Oncol Res, 1999,5(2) : 104-106. 被引量:1
  • 8Takehana T, Kunitomo K, Kono K, et al. Status of C-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzymelinked immuno-sorhent assay[J].Int J Cancer,2002,98(6): 833-837. 被引量:1
  • 9Vizoso F J, Corte MD, Alvarez A, et al. Membranous levels of C-erbB-2 oncoprotein in gastric cancer: their relationship with clinicopathological parameters and their prognostic significance[J]. Int J Biol Markers, 2004,19 (4):268-274. 被引量:1
  • 10Kim MA,Jung EJ, Lee HS, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction[J].Hum Pathol, 2007,38(9) : 1386- 1393. 被引量:1

共引文献13

同被引文献53

  • 1张春容,杨天文.环氧合酶-2的表达与胃癌发生的关系及Hp感染对COX-2其表达的影响[J].中国老年学杂志,2014,34(1):68-69. 被引量:6
  • 2Wang X K, Fu L W. Interaction of tyrosine kinase inhibitors withthe MDR-related ABC transporter proteins [ J ]. Curr Drug Metab,2010,11(7) :618 -28. 被引量:1
  • 3Bai F,Wang C,Lu Q, et al. Nanoparticle-mediated drug deliveryto tumor neovasculature to combat P-gp expressing multidrug resist-ant cancer[ J]. Biomaterials, 2013 ,34(26) :6163 -74. 被引量:1
  • 4Juliano R L, Ling V. A surface glycoprotein modulation drug per-meability in Chinese hamster ovary cell mutants [ J]. Biochim Bio-phys Acta, 1976,455(1) :152 -62. 被引量:1
  • 5Modrak D E,Gold D Y, Goldenberg D M. Sphingolipid targets incancer therapy [ J]. Mol Cancer Ther,2006,5(2) ;200 - 8. 被引量:1
  • 6Liu Y Y, Patwardhan G A, Xie P, et al. Glucosylceramide syn-thase ,a factor in modulating drug resistance,is overexpressed inmetastatic breast carcinoma[ J]. Int J Oncol,2011 ,39(2) :425 -31. 被引量:1
  • 7Gouaze-Andersson V,Yu J Y,Kreitenberg A J, ei al. Ceramideand glucosylceramide upregulate expression of the multidrug resist-ance gene MDR1 in cancer cells [ J ]. Biochim Biophys Acta,2007,1771(12) :1407 -17. 被引量:1
  • 8Liu Y Y, Gupta V, Patwardhan G A, et al. Glucosylceramide syn- thase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling [ J ]. Mol Canc- er, 2010,9 : 145. 被引量:1
  • 9Gerrard G, Butters T D, Ganeshaguru K, et al. Glucosylceramide synthase inhibitors sensitise CLL ceils to cytotoxic agents without re- versing P-gp functional activity[J]. EurJ Pharmacol, 2009,609(1 -3) :34 -9. 被引量:1
  • 10胡萍萍,陈同钰,田波,蒋敬庭,邓海峰,李敏.GCS在人乳腺癌细胞多药耐药中的作用及与P-gp的关系[J].实用肿瘤杂志,2007,22(6):488-491. 被引量:4

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部